AIV Logo AIV Assistant

Loading...

 Logo Bavarian Nordic A/S - BAVA.CO Open Bavarian Nordic A/S in new tab

239.70
P/E
13.42
EPS
18.00
P/B
1.56
ROE
0.13
Beta
1.05

239.7000

239.700

Daily: +0.00%
Key Metrics

Earnings date: Nov. 14, 2025

P/E: 13.42

EPS: 18.00

Book Value: 154.76

Price to Book: 1.56

Debt/Equity: 1.13

% Insiders: 0.000%

Growth

Revenue Growth: 0.16%

Earnings Growth: 0.36%

Estimates

Forward P/E: 13.47

Forward EPS: 17.93

 Logo About Bavarian Nordic A/S - (BAVA.CO)

Country: Denmark

Sector: Health Care

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion